<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04453735</url>
  </required_header>
  <id_info>
    <org_study_id>REK 54041</org_study_id>
    <nct_id>NCT04453735</nct_id>
  </id_info>
  <brief_title>MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study</brief_title>
  <official_title>MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins are cornerstone treatment in secondary cardiovascular disease (CVD) prevention.
      Today, statin non-adherence (patients not taking their prescribed drug) remains a major
      public health concern, leading to adverse outcomes in terms of morbidity, mortality and
      healthcare costs. The principal reason for statin non-adherence and discontinuation is
      statin-associated muscle symptoms (SAMS). Objective SAMS diagnostics do not exist. We aim to
      unravel the pathophysiology of SAMS and develop diagnostic tools to differentiate real SAMS
      from muscle symptoms not related to the statin, among coronary patients with self-perceived
      SAMS. In this follow-up study we aims to determine the effect of 7 weeks open treatment with
      atorvastatin 40 mg/day, followed by 7 weeks open treatment with no lipid lowering treatment,
      on muscle symptom intensity in patients classified with confirmed statin-associated muscle
      symptoms (SAMS) (i.e. statin-dependent muscle side-effects) and non-SAMS in the MUscle
      Side-Effects of atorvastatin in coronary patients (MUSE) randomized double blinded cross-over
      trial.

      We have developed novel methods that will be used to measure atorvastatin metabolites and
      drug effect biomarkers directly in skeletal muscle and blood . The diagnostic accuracy of
      these biomarkers to differentiate real SAMS from non-SAMS will be evaluated. A new diagnostic
      tool may potentially be implemented to assess SAMS in the individual patient and enable
      personalized follow-up. It may also represent an important tool in the communication with
      patients misattributing their muscle symptoms to statins. The long-term results may be better
      quality of life and reduced morbidity, mortality and healthcare costs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 19, 2020</start_date>
  <completion_date type="Anticipated">December 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective, open, intervention study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual mean difference in muscular symptom intensity measured with a 0 (no symptoms) to 10 (worst imaginable symptoms) Visual Analogue Scale (VAS) score between treatment periods with statin and &quot;no statin treatment&quot;</measure>
    <time_frame>16 weeks following study start</time_frame>
    <description>Individual mean difference in muscular symptom (i.e. pain, aching, tenderness, stiffness, cramp and/or weakness) intensity between treatment periods with statin and no statin, reported by the patients over the last three weeks (i.e. week 4-7) measured with a 0 (no symptoms) to 10 (worst imaginable symptoms) Visual Analogue Scale (VAS) score with aggregated data from each subscale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who report muscle symptoms on atorvastatin treatment and not on statin (dichotomous Statin Associated Muscle Symptom classification)</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between atorvastatin-related variables in muscle and the primary study endpoint. The ability of atorvastatin-related variables in muscle to differentiate confirmed SAMS and non-SAMS</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between atorvastatin-related variables in plasma vs. muscle and PBMC vs. muscle. Correlation between atorvastatin-related variables in blood and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between atorvastatin: HMGCR in muscle and the primary study endpoint. The ability of atorvastatin:HMGCR in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between atorvastatin:HMGCR in PBMC vs. muscle. Correlation between atorvastatin:HMGCR in PBMC and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mevalonate pathway intermediates in muscle and the primary study endpoint. The ability of mevalonate pathway intermediates in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mevalonate pathway intermediates in plasma vs. muscle and PBMC vs. muscle. Correlation between mevalonate pathway intermediates in blood and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mitochondrial respiratory enzymes in muscle and the primary study endpoint. The ability of mitochondrial respiratory enzymes in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mitochondrial respiratory enzymes in PBMC vs. muscle. Correlation between mitochondrial respiratory enzymes in PMBC and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the FKBP1A:RyR1 ratio in muscle and the primary study endpoint. The ability of the FKBP1A:RyR1 ratio in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the FKBP1A:RyR1 ratio in PBMC vs. muscle. Correlation between the FKBP1A:RyR1 ratio in PBMC and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between caspase 3 signalling in muscle and the primary study endpoint. The ability of caspase 3 signalling in muscle to differentiate confirmed SAMS and non-SAMS.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between caspase 3 signalling in PBMC vs. muscle. Correlation between caspase 3 signalling in blood and the primary study endpoint.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in muscle response variables between atorvastatin period and non-statin period.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of molecular effects in blood vs. muscle. Difference in blood response variables between atorvastatin period and non-statin period. Correlation between atorvastatin-related variables and response variables in blood.</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statin adherence measured with indirect methods and by parent drug and metabolite concentrations in blood</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset CHD symptoms. Intolerable muscle symptoms leading to discontinuation from the treatment arm. Creatine kinase (CK) &gt; 10 times upper limit of the normal range or alaninaminotransferase (ALT) &gt; 3 times upper normal limit</measure>
    <time_frame>16 weeks following study start</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Statin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin mylan 40 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No statin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin mylan 40 Mg Oral Tablet</intervention_name>
    <description>Oral tablet on regular prescription</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in the MUSE trial (Eudract nr. 2018-004261-14) and still fulfilling the
             study entry criteria: First or recurrent diagnosis (myocardial infarction) or
             treatments (PCI or CABG) for a CHD event 12-42 months prior to study start.

        Exclusion Criteria:

          -  First or recurrent diagnosis (myocardial infarction) or treatments (PCI or CABG) for a
             CHD event the a) past 12 months prior to study start in high risk patients (i.e. at
             least one of following comorbid conditions: systolic heart failure, &gt;1 previous
             myocardial infarction, kidney failure, diabetes, and smokers) and b) the past 6 months
             prior to study start in low risk patients without any of the co-morbid conditions
             mentioned above and in patients who are not taking a statin at all.

          -  Patients with symptomatic peripheral artery disease and patients with familial
             hypercholesterolemia

          -  Patient has any contraindications for atorvastatin listed in the Summary of Product
             Characteristics (i.e. known hypersensitivity to the ingredients, acute liver failure/
             ALT &gt; 3 times upper limit of the normal range in blood at study start, pregnancy and
             breastfeeding )

          -  History of previous rhabdomyolysis, myopathy or liver failure due to statin treatment
             with CK &gt; 10 times upper limit of the normal range or ALT &gt; 3 times upper limit of the
             normal range.

          -  Any condition (e.g. psychiatric illness, dementia) or situation, that in the
             investigator's opinion could put the subject at significant risk, confound the study
             results, interfere significantly with the subject participation in the study, or
             rendering informed consent unfeasible

          -  Short life expectancy (&lt;12 months) due to other medical conditions

          -  Not being able to understand Norwegian.

          -  Women of childbearing potential defined as all premenopausal female.

          -  Participation in another randomized clinical trial

          -  Classified with significantly more muscle symptoms on placebo than on atorvastatin in
             the MUSE trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>john munkhaugen, MD, PhD</last_name>
    <phone>97524194</phone>
    <email>johmun@vestreviken.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kari Peersen, PhD</last_name>
    <email>kari.peersen@siv.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vestre Viken HF, Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <state>Buskerud</state>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>john munkhaugen, MD, PhD</last_name>
      <phone>32803000</phone>
      <email>johmun@vestreviken.no</email>
    </contact>
    <contact_backup>
      <last_name>kari Peersen, PhD</last_name>
      <email>kari.peersen@siv.no</email>
    </contact_backup>
    <investigator>
      <last_name>John Munkhaugen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Vestfold</name>
      <address>
        <city>TÃ¸nsberg</city>
        <state>Vestfold</state>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Kari Peersen, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>June 28, 2020</last_update_submitted>
  <last_update_submitted_qc>June 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data will be made available for other researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be available within 5 years of study completion</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

